| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bicalutamide | GDSC1000 | pan-cancer | AAC | 0.056 | 0.1 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | -0.27 | 0.1 |
| mRNA | BMS-270394 | CTRPv2 | pan-cancer | AAC | -0.06 | 0.1 |
| mRNA | Cerulenin | CTRPv2 | pan-cancer | AAC | -0.053 | 0.1 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | 0.049 | 0.1 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.058 | 0.1 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | -0.088 | 0.1 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | -0.053 | 0.1 |
| mRNA | SB 505124 | GDSC1000 | pan-cancer | AAC | -0.056 | 0.1 |